A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)

OBJECTIVE: In recurrent ovarian cancer (ROC), there is a high demand on effective therapies with a mild toxicity profile. Treosulfan is an alkylating agent approved as oral (p.o.) and intravenous (i.v.) formulation for the treatment of recurrent ovarian cancer. Data on safety and efficacy for either...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehouli, Jalid, Tomè, Oliver, Dimitrova, Desislava, Camara, Oumar, Runnebaum, Ingo Bernhard, Tessen, Hans Werner, Rautenberg, Beate, Chekerov, Radoslav, Muallem, Mustafa Zelal, Lux, Michael Patrick, Trarbach, Tanja, Gitsch, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306340/
https://www.ncbi.nlm.nih.gov/pubmed/27896440
http://dx.doi.org/10.1007/s00432-016-2307-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306340/
https://www.ncbi.nlm.nih.gov/pubmed/27896440
http://dx.doi.org/10.1007/s00432-016-2307-0

Ejemplares similares